We aimed to determine whether comparisons of FOLH1 expression derived from large-scale transcriptomic profiling of tumor cohorts and of related normal tissue could determine tumor types for which PSMA-targeting theranostics may have utility. This evidence concerns the gene FOLH1 and neoplasm.